Indications and Usage for COAGADEXCOAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
Routine prophylaxis to reduce the frequency of bleeding episodes• On-demand treatment and control of bleeding episodes•
Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency• Contraindication for COAGADEX
Important Safety Information for COAGADEXPlease see complete Prescribing Information for COAGADEX.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
©2026 Kedrion Biopharma Inc. All Rights Reserved.
X.0016.USA.26 March 2026
References: 1. Medical and Scientific Advisory Council (MASAC) of the National Bleeding Disorders Foundation. MASAC Document #290. 2. COAGADEX (Coagulation Factor X, Human) Prescribing Information. Durham, NC: BPL Limited. 2024. 3. Liesner R, et al. Haemophilia. 2018;24(6):941-949. 4. Austin S, et al. Haemophilia. 2016;22:419-425. 5. Escobar M, et al. Haemophilia. 2016;22:713-720.
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.
®
©2026 Kedrion Biopharma Inc. All Rights Reserved.
X.0016.USA.26 March 2026